At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 89 enrolled
Drug / intervention
belinostat, carboplatin, paclitaxel +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label Randomized Phase II Trial of Belinostat (PXD101) in Combination With Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Previously Untreated Carcinoma of Unknown Primary
In Brief
A Phase 2 clinical trial evaluating belinostat, carboplatin, paclitaxel and carboplatin, paclitaxel for Carcinoma of Unknown Primary. Completed, enrolled 89 participants across 23 sites in 4 countries.
Detailed Summary
The purpose of this study is to assess efficacy and safety of belinostat in combination with carboplatin and paclitaxel in patients with previously untreated carcinoma of unknown primary.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma of Unknown Primary
CountriesDenmark, France, Germany, United States
CollaboratorsSpectrum Pharmaceuticals, Inc
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2009
First PostedApr 2009
Primary CompletionDec 2012
TodayJul 2026
First PostedApr 1, 2009
Enrollment StartFeb 1, 2009
Primary CompletionDec 1, 2012
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 17.3 years ago
Interventions
belinostat, carboplatin, paclitaxeldrug
carboplatin, paclitaxeldrug